Genmab — April 2017

Budweis

Bør EU godkendelsen ikke komme i denne uge?

bibob

Ca. 67 dg. fra 23 februar. Omkring D. 1 maj.

E_L

Could be this week, press release Genmab February 24 said "A final decision by the European Commission is anticipated within two months."

E_L

And NICE /UKsecond commitee meeting April 20, but i dont know if they will make any announcements, as it says Expected
publication date July 2017

bibob

http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/004077/WC500222148.pdf Nederst på siden står der 67 dg.

digafarm

Det må så være senest d. 27/4

E_L

EMA must be the correct one indeed. Guess Rachel didn't read the small print A few extra days of nervousness...

JKY_VH

I'm not worried about the approval. Dont worry be happy:-)

digafarm

Probably the friday news we have been longing for in two weeks time

bibob

God morgen

bibob

Ser ud til at GMXAY alligevel blev handlet i går. + 0,67. %.

JKY_VH

God morgen

transalp

Go morgen

E_L

FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer

Helge_LarsenPI-redaktør

God morgen.

Sibelius

@GlobalMacro, Thanks for sharing your thoughts. Totally agree with your line of thought re how investors and analysts need to see gradual proof of the pudding before upping targets and expectations.

Sibelius

I also agree that it is unlikely that Genmab remain independent for ten years more - or five for that matter.

Sibelius

However, before getting lost in P/E calculations etc., we should also consider what the strategy of the company is, and how this will change the operations and earings multiples.

Sibelius

Genmab will - if strategy becomes action and reality - become a completely different animal.

Sibelius

This will include a lot more investment - and risk - in new R&D. Also, taking greater responsibility for approvals, market launch and global sales of new products will lead to much higher leverage and roll-out risks.